Stephane Ragusa

About Stephane Ragusa

Stéphane Ragusa is the founder and Chief Executive Officer of PREDILIFE, a French pioneer in predictive medicine listed on Euronext Growth since 2018. He holds a degree from École Polytechnique, a PhD in biology, and serves as an associate professor in statistics applied to medicine at Sorbonne University. His profile combines advanced scientific training with deep expertise in data-driven medical modeling, risk prediction and preventive healthcare. That multidisciplinary background is central to his career and to the strategy he has led at PREDILIFE. Ragusa’s professional path began in academic and research settings, where he taught and worked on statistical approaches applied to biology and medicine. While teaching mathematics applied to medicine and working at the Gustave Roussy cancer center, he developed the idea that many serious diseases might be anticipated earlier, allowing more effective prevention. This insight became the foundation of PREDILIFE, which he created in 2004. Since then, he has guided the company from a research-oriented project into a commercial healthtech business focused on predictive tests and personalized prevention. Under his leadership, PREDILIFE developed medical devices that combine established medical methods with artificial intelligence and big data to estimate the risk of serious diseases, especially cancer. After 14 years of research and development, the company secured medical device certification and began rolling out predictive check-ups in France and abroad. Ragusa’s leadership has also been marked by a clear long-term vision: making predictive medicine accessible to everyone and encouraging individuals to take an active role in their health through personalized follow-up. His role at PREDILIFE reflects a strong blend of scientific credibility, entrepreneurial drive and regulatory discipline, positioning him as a key executive in French listed health innovation.